AlphAIAlphAI — Financial news for AI agents
manilatimes.netJUL 62 min read$DBVT

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies (Euronext: DBV; Nasdaq: DBVT) published its half-year report on its AMF-regulated liquidity contract with ODDO BHF. Liquidity account assets rose from 41,159 shares and €432,367.25 (July 1, 2018) to 74,580 shares and €527,891.63 (Dec 31, 2025) and 146,321 shares and €396,088.22 (June 30, 2026). Jan 1–Jun 30, 2026: 1,989 buys and 2,012 sells; purchases 2,707,915 shares (€8.84m) and sales 2,636,174 shares (€8.70m).

Original reporting
manilatimes.net
Published Jul 6, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF — source image
Source · manilatimes.net
Decision brief

The 30-second read

$DBVTNeutralLow
01

Why it matters

The report updates the liquidity account’s share and euro balances and summarizes buy/sell transaction volumes for Jan 1–Jun 30, 2026.

02

Market read

This is a compliance/routine liquidity-contract disclosure with updated balances and transaction volumes through June 30, 2026.

03

What to watch

Liquidity-contract activity can affect spreads/prints, but the article provides no linkage to order-book behavior, spreads, or any change in contract parameters.

Relevance 4/10Novelty 3/10Timing: post-market / published July 6, 2026 with liquidity-account balances through June 30, 2026

Background

DBV Technologies’ liquidity contract with ODDO BHF is implemented under AMF Decision No. 2021-01 and is reported on a half-year basis.

Company-level read

Ticker impact

$DBVTNeutralMedium confidence
Context

DBV Technologies reports its AMF-regulated half-year liquidity contract activity, including liquidity-account share and cash balances as of June 30, 2026.

Expected impact

Low near-term impact; any effect is likely limited to liquidity/volatility rather than valuation.

Evidence & confidence

The disclosure is a routine regulatory liquidity-contract update with balance/transaction counts; it does not introduce new clinical, financial, or strategic information.

Market effects

Sector

Minimal; liquidity-contract disclosures are company-specific and do not signal sector-wide changes.

Regional

Limited to Euronext/Nasdaq trading microstructure for DBV/DBVT.

Global

Low; no cross-border deal, regulator action, or clinical milestone is disclosed.

Counterpoint

What could challenge this read

Traders focused on microstructure could still monitor whether liquidity-account balances are rising or falling as a proxy for near-term trading support.

Key entities

  • issuer
    DBV Technologies

    Late-stage biopharmaceutical company; subject of the liquidity-contract half-year report.

  • counterparty
    ODDO BHF

    Broker implementing the liquidity contract for DBV Technologies shares under AMF rules.

  • regulator
    AMF

    French market regulator whose decision governs liquidity contracts on equity securities.

Read at source← All news

Related articles

SEP 29
$DBVTMedAI 8/10

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

DBV Technologies submitted a Biologics License Application to the FDA for its VIASKIN® Peanut Patch for children aged 4-7. The application is supported by positive Phase 3 trial results and seeks Priority Review. The patch uses epicutaneous immunotherapy to treat peanut allergies. DBV's shares trade on Euronext Paris and Nasdaq.

globenewswire.com2 min
JUL 30
$DBVTMedAI 8/10

DBV Technologies S.A.: DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Capital Market: DBVT) (the "Company"), a late-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the...

finanznachrichten.de4 min
JUL 17
$DBVTMedAI 8/10

DBV Technologies S.A.: DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales

DBV Technologies said it filed an automatically effective SEC Form S-3ASR shelf registration to refresh its at-the-market program for sales of up to $150 million of American Depositary Shares. The ADSs represent five ordinary shares and the program is under a Sept. 5, 2025 sales agreement with Citizens JMP Securities. Net proceeds would fund manufacturing expansion, BLAs, Viaskin Peanut launch prep, development, and working capital.

finanznachrichten.de2 min
JUL 16
$DBVTMed

DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

DBV Technologies S.A. (DBVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d156695dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Press Release Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update • Continued productive engagement with the FDA in support of the BLA for the VI

SEC EDGAR 8-K6 min
JUL 16
$DBVTMedAI 8/10

DBV Technologies S.A.: DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

DBV Technologies reported Q2 and half-year 2026 results. It said FDA engagement for the VIASKIN Peanut Patch BLA for children ages 4-7 continues, with BLA submission expected in Q3 2026 and no additional data requested. Cash and cash equivalents were $174.9 million at June 30, 2026, funding into Q3 2027. Net loss was $98.0 million for six months.

finanznachrichten.de6 min